Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes

Yuka Toyoshima, Oksana Gavrilova, Shoshana Yakar, William Jou, Stephanie Pack, Zeenat Asghar, Michael Wheeler, Derek LeRoith

Research output: Contribution to journalArticle

Abstract

Leptin has metabolic effects on peripheral tissues including muscle, liver, and pancreas, and it has been successfully used to treat lipodystrophic diabetes, a leptin-deficient state. To study whether leptin therapy can be used for treatment of more common cases of type 2 diabetes, we used a mouse model of type 2 diabetes (MKR mice) that show normal leptin levels and are diabetic due to a primary defect in both IGF-I and insulin receptors signaling in skeletal muscle. Here we show that leptin administration to the MKR mice resulted in improvement of diabetes, an effect that was independent of the reduced food intake. The main effect of leptin therapy was enhanced hepatic insulin responsiveness possibly through decreasing gluconeogenesis. In addition, the reduction of lipid stores in liver and muscle induced by enhancing fatty acid oxidation and by inhibiting lipogenesis, led to an improvement of the lipotoxic condition. Our data suggest that leptin could be a potent anti-diabetic drug in cases of type 2 diabetes that are not leptin deficient.

Original languageEnglish (US)
Pages (from-to)4024-4035
Number of pages12
JournalEndocrinology
Volume146
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Leptin
Hyperglycemia
Type 2 Diabetes Mellitus
Insulin Resistance
Liver
Muscles
IGF Type 1 Receptor
Lipogenesis
Gluconeogenesis
Insulin Receptor
Pancreas
Skeletal Muscle
Fatty Acids
Eating
Insulin
Lipids
Therapeutics
Pharmaceutical Preparations

Keywords

  • Leptin
  • Lipotoxicity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Toyoshima, Y., Gavrilova, O., Yakar, S., Jou, W., Pack, S., Asghar, Z., ... LeRoith, D. (2005). Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology, 146(9), 4024-4035. https://doi.org/10.1210/en.2005-0087

Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. / Toyoshima, Yuka; Gavrilova, Oksana; Yakar, Shoshana; Jou, William; Pack, Stephanie; Asghar, Zeenat; Wheeler, Michael; LeRoith, Derek.

In: Endocrinology, Vol. 146, No. 9, 09.2005, p. 4024-4035.

Research output: Contribution to journalArticle

Toyoshima, Y, Gavrilova, O, Yakar, S, Jou, W, Pack, S, Asghar, Z, Wheeler, M & LeRoith, D 2005, 'Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes', Endocrinology, vol. 146, no. 9, pp. 4024-4035. https://doi.org/10.1210/en.2005-0087
Toyoshima, Yuka ; Gavrilova, Oksana ; Yakar, Shoshana ; Jou, William ; Pack, Stephanie ; Asghar, Zeenat ; Wheeler, Michael ; LeRoith, Derek. / Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. In: Endocrinology. 2005 ; Vol. 146, No. 9. pp. 4024-4035.
@article{919093ea3c5743a995f987c0c774fd9c,
title = "Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes",
abstract = "Leptin has metabolic effects on peripheral tissues including muscle, liver, and pancreas, and it has been successfully used to treat lipodystrophic diabetes, a leptin-deficient state. To study whether leptin therapy can be used for treatment of more common cases of type 2 diabetes, we used a mouse model of type 2 diabetes (MKR mice) that show normal leptin levels and are diabetic due to a primary defect in both IGF-I and insulin receptors signaling in skeletal muscle. Here we show that leptin administration to the MKR mice resulted in improvement of diabetes, an effect that was independent of the reduced food intake. The main effect of leptin therapy was enhanced hepatic insulin responsiveness possibly through decreasing gluconeogenesis. In addition, the reduction of lipid stores in liver and muscle induced by enhancing fatty acid oxidation and by inhibiting lipogenesis, led to an improvement of the lipotoxic condition. Our data suggest that leptin could be a potent anti-diabetic drug in cases of type 2 diabetes that are not leptin deficient.",
keywords = "Leptin, Lipotoxicity, Type 2 diabetes",
author = "Yuka Toyoshima and Oksana Gavrilova and Shoshana Yakar and William Jou and Stephanie Pack and Zeenat Asghar and Michael Wheeler and Derek LeRoith",
year = "2005",
month = "9",
doi = "10.1210/en.2005-0087",
language = "English (US)",
volume = "146",
pages = "4024--4035",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes

AU - Toyoshima, Yuka

AU - Gavrilova, Oksana

AU - Yakar, Shoshana

AU - Jou, William

AU - Pack, Stephanie

AU - Asghar, Zeenat

AU - Wheeler, Michael

AU - LeRoith, Derek

PY - 2005/9

Y1 - 2005/9

N2 - Leptin has metabolic effects on peripheral tissues including muscle, liver, and pancreas, and it has been successfully used to treat lipodystrophic diabetes, a leptin-deficient state. To study whether leptin therapy can be used for treatment of more common cases of type 2 diabetes, we used a mouse model of type 2 diabetes (MKR mice) that show normal leptin levels and are diabetic due to a primary defect in both IGF-I and insulin receptors signaling in skeletal muscle. Here we show that leptin administration to the MKR mice resulted in improvement of diabetes, an effect that was independent of the reduced food intake. The main effect of leptin therapy was enhanced hepatic insulin responsiveness possibly through decreasing gluconeogenesis. In addition, the reduction of lipid stores in liver and muscle induced by enhancing fatty acid oxidation and by inhibiting lipogenesis, led to an improvement of the lipotoxic condition. Our data suggest that leptin could be a potent anti-diabetic drug in cases of type 2 diabetes that are not leptin deficient.

AB - Leptin has metabolic effects on peripheral tissues including muscle, liver, and pancreas, and it has been successfully used to treat lipodystrophic diabetes, a leptin-deficient state. To study whether leptin therapy can be used for treatment of more common cases of type 2 diabetes, we used a mouse model of type 2 diabetes (MKR mice) that show normal leptin levels and are diabetic due to a primary defect in both IGF-I and insulin receptors signaling in skeletal muscle. Here we show that leptin administration to the MKR mice resulted in improvement of diabetes, an effect that was independent of the reduced food intake. The main effect of leptin therapy was enhanced hepatic insulin responsiveness possibly through decreasing gluconeogenesis. In addition, the reduction of lipid stores in liver and muscle induced by enhancing fatty acid oxidation and by inhibiting lipogenesis, led to an improvement of the lipotoxic condition. Our data suggest that leptin could be a potent anti-diabetic drug in cases of type 2 diabetes that are not leptin deficient.

KW - Leptin

KW - Lipotoxicity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=23844556589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844556589&partnerID=8YFLogxK

U2 - 10.1210/en.2005-0087

DO - 10.1210/en.2005-0087

M3 - Article

C2 - 15947005

AN - SCOPUS:23844556589

VL - 146

SP - 4024

EP - 4035

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -